Transition from Oxycodone to Buprenorphine/Naloxone in a Hospitalized Patient with Sickle Cell Disease: A Case Report

被引：0

作者：

Sarah Leyde

Leslie Suen

Lisa Pratt

Triveni DeFries

机构：

[1] University of Washington,Division of General Internal Medicine, Department of Medicine, Harborview Medical Center

[2] Philip R. Lee Institute of Health Policy Studies,National Clinician Scholar Program

[3] University of California,San Francisco Department of Public Health

[4] San Francisco,Division of General Internal Medicine, Department of Medicine, San Francisco General Hospital and Trauma Center

[5] San Francisco Veteran Affairs Medical Center,undefined

[6] Jail Health Services,undefined

[7] University of California,undefined

来源：

Journal of General Internal Medicine | 2022年 / 37卷

关键词：

sickle cell disease; buprenorphine; chronic pain; vaso-occlusive episode;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Buprenorphine is increasingly used to treat pain in patients with sickle cell disease but optimal timing and approach for transitioning patients from full agonist opioids to buprenorphine is unknown. We present the case of a 22-year-old woman with sickle cell disease and acute on chronic pain who transitioned from high-dose oxycodone to buprenorphine/naloxone during a hospital stay for vaso-occlusive episode. Utilizing a microdosing approach to minimize pain and withdrawal, buprenorphine/naloxone was gradually uptitrated while she received full agonist opioids. During the transition, she experienced some withdrawal in the setting of swallowed buprenorphine/naloxone tablets, which were intended to be dosed sublingually. Nevertheless, the transition was tolerable to the patient and her pain and function significantly improved with buprenorphine treatment. This case also highlights the challenges and unique considerations that arise when providing care for the hospitalized patient who is also incarcerated.

引用

页码：1281 / 1285

页数：4

共 31 条

[1]

Brandow AM(2020)American society of hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv 4 2656-2701

[2]

Carroll CP(2019)Use of buprenorphine/naloxone in ameliorating acute care utilization and chronic opioid use in adults with sickle cell disease Blood 134 790-790

[3]

Creary S(2016)Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method SAR. 7 99-105

[4]

Osunkwo I(2019)A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and acute care settings Can J Addict 10 41-50

[5]

Veeramreddy P(2019)Transitioning hospitalized patients with opioid use disorder from methadone to buprenorphine without a period of opioid abstinence using a microdosing protocol Pharmacotherapy. 39 1023-1029

[6]

Arnall J(2021)Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease Pediatr Blood Cancer 68 661-680

[7]

Hämmig R(2005)Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence Clin Pharmacokinet 44 1-11

[8]

Kemter A(2014)Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy - PubMed Drug Alcohol Depend 144 627-632

[9]

Strasser J(2006)Buprenorphine induces ceiling in respiratory depression but not in analgesia Br J Anaesth 96 1902-1903

[10]

Ghosh SM(2020)When actions speak louder than words - racism and sickle cell disease N Engl J Med 383 undefined-undefined

← 1 2 3 4 →